nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

14.09.2019 | Original Article – Clinical Oncology

PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy

verfasst von: Zhenlin Yang, Jiachen Xu, Renda Li, Yibo Gao, Jie He

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Combined immunotherapy with anti-programmed cell death-ligand 1 (PD-L1) and an inhibitor of cluster of differentiation 47 (CD47) have exhibited preliminary anti-tumor effect. Our study attempted to describe the PD-L1/CD47 expression status in pulmonary sarcomatoid carcinoma (PSC), and explore its survival impact and relevance with cytotoxic T lymphocytes and macrophages infiltration.

Methods

148 patients with PSC who underwent surgeries were retrospectively reviewed. Tissue microarrays were conducted for immunohistochemistry (IHC) of PD-L1, CD47, CD8 and CD68.

Results

54 (36.5%) and 78 (52.7%) cases were positive for PD-L1 and CD47, respectively, and 36 (24.3%) of them demonstrated PD-L1/CD47 co-expression. There was a significant correlation between PD-L1 and CD47 expression (P = 0.011). The median overall survival (OS) was 22.5 months (range 0.9–102.4 months). The univariate analysis demonstrated a significantly worse OS in cases with CD47 expression (hazard ratio [HR], 1.66; 95% CI, 1.14–2.42, P = 0.008) and PD-L1/CD47 co-expression (HR, 1.75; 95% CI, 1.15–2.67, P = 0.009). The multivariate analysis demonstrated PD-L1/CD47 co-expression (HR, 1.83; 95% CI, 1.17–2.87, P = 0.008), T stage, M stage, completeness of resection and adjuvant therapy were independent prognostic factors for OS. There was a significant relevance between PD-L1 expression and PD-L1/CD47 co-expression with higher densities of CD8-positive T lymphocytes (P = 0.004, 0.012, respectively) and CD68-positive macrophages (P = 0.026, 0.034, respectively).

Conclusion

We demonstrated the PD-L1/CD47 co-expression status in PSC. PD-L1 expression correlated with CD47 expression, and PD-L1/CD47 co-expression correlated with poorer prognosis and may serve as a predictive biomarker for combined dual-targeting immunotherapy in PSC patients.

Ansell S, Chen RW, Flinn IW, Maris MB, O’Connor OA, Johnson LD, Irwin M, Petrova PS, Uger RA, Sievers EL (2016) A Phase 1 study of TTI-621, a novel immune checkpoint inhibitor targeting CD47, in patients with relapsed or refractory hematologic malignancies. Blood 28:1812CrossRef

Bae HM, Min HS, Lee SH, Kim DW, Chung DH, Lee JS, Kim YW, Heo DS (2007) Palliative chemotherapy for pulmonary pleomorphic carcinoma. Lung Cancer 58:112–115CrossRefPubMed

Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, Gouw AM, Baylot V, Gütgemann I, Eilers M, Felsher DW (2016) MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352:227–231. https://doi.org/10.1126/science.aac9935 CrossRefPubMedPubMedCentral

Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, Gascoyne RD, Lossos IS, Levy R, Weissman IL, Majeti R (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142:699–713. https://doi.org/10.1016/j.cell.2010.07.044 CrossRefPubMedPubMedCentral

Fallet V, Saffroy R, Girard N, Mazieres J, Lantuejoul S, Vieira T, Rouquette I, Thivolet-Bejui F, Ung M, Poulot V, Schlick L, Moro-Sibilot D, Antoine M, Cadranel J, Lemoine A, Wislez M (2015) High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the Lung Carta TM Panel: exploring therapeutic targets. Ann Oncol 26:1748–1753. https://doi.org/10.1093/annonc/mdv232 CrossRefPubMed

Galli S, Zlobec I, Schürch C, Perren A, Ochsenbein AF, Banz Y (2015) CD47 protein expression in acute myeloid leukemia: a tissue microarray-based analysis. Leuk Res 39:749–756. https://doi.org/10.1016/j.leukres.2015.04.007 CrossRefPubMed

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028. https://doi.org/10.1056/NEJMoa1501824 CrossRefPubMed

Gholamin S, Mitra SS, Feroze AH, Liu J, Kahn SA, Zhang M, Esparza R, Richard C, Ramaswamy V, Remke M, Volkmer AK, Willingham S, Ponnuswami A, McCarty A, Lovelace P, Storm TA, Schubert S, Hutter G, Narayanan C, Chu P, Raabe EH, Harsh G, Taylor MD, Monje M, Cho YJ, Majeti R, Volkmer JP, Fisher PG, Grant G, Steinberg GK, Vogel H, Edwards M, Weissman IL, Cheshier SH (2017) Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aaf2968 CrossRefPubMed

Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, Gupta R, Tsai JM, Sinha R, Corey D, Ring AM, Connolly AJ, Weissman IL (2017) PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545:495–499. https://doi.org/10.1038/nature22396 CrossRefPubMedPubMedCentral

Gu L, Xu Y, Chen Z, Pan Y, Lu S (2015) Clinical analysis of 95 cases of pulmonary sarcomatoid carcinoma. Biomed Pharmacother 76:134–140. https://doi.org/10.1016/j.biopha.2015.10.009 CrossRefPubMed

Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563–567. https://doi.org/10.1038/nature14011 CrossRefPubMedPubMedCentral

Hou J, Xing LH, Yuan YF (2018) A clinical analysis of 114 cases of sarcomatoid carcinoma of the lung. Clin Exp Med 18:555–562. https://doi.org/10.1007/s10238-018-0517-2 CrossRefPubMed

Huang SY, Shen SJ, Li XY (2013) Pulmonary sarcomatoid carcinoma: a clinicopathologic study and prognostic analysis of 51 cases. World J Surg Oncol 11:252. https://doi.org/10.1186/1477-7819-11-252 CrossRefPubMedPubMedCentral

Ingram JR, Blomberg OS, Sockolosky JT, Ali L, Schmidt FI, Pishesha N, Espinosa C, Dougan SK, Garcia KC, Ploegh HL, Dougan M (2017) Localized CD47 blockade enhances immunotherapy for murine melanoma. Proc Natl Acad Sci USA 114:10184–10189. https://doi.org/10.1073/pnas.1710776114 CrossRefPubMedPubMedCentral

Kim S, Kim M-Y, Koh J, Go H, Lee DS, Jeon YK, Chung DH (2015) Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: comparison of sarcomatous and carcinomatous areas. Eur J Cancer 51:2698–2707. https://doi.org/10.1016/j.ejca.2015.08.013 CrossRefPubMed

Latour S, Tanaka H, Demeure C, Mateo V, Rubio M, Brown EJ, Maliszewski C, Lindberg FP, Oldenborg A, Ullrich A, Delespesse G, Sarfati M (2001) Bidirectional negative regulation of human T and dendritic cells by CD47 and its cognate receptor signal-regulator protein-alpha: down-regulation of IL-12 responsiveness and inhibition of dendritic cell activation. J Immunol 167:2547–2554CrossRefPubMed

Lesokhin AM, Callahan MK, Postow MA, Wolchok JD (2015) On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci Transl Med 7:280sr1. https://doi.org/10.1126/scitranslmed.3010274 CrossRefPubMed

Li Y, Lu S, Xu Y, Qiu C, Jin C, Wang Y, Liu Z, Kong B (2017) Overexpression of CD47 predicts poor prognosis and promotes cancer cell invasion in high-grade serous ovarian carcinoma. Am J Transl Res 9:2901–2910PubMedPubMedCentral

Lin Y, Yang H, Cai Q, Wang D, Rao H, Lin S, Long H, Fu J, Zhang L, Lin P, Xu G, Rong T, Xiong X, Ma G, Liang Y (2016) Characteristics and prognostic analysis of 69 patients with pulmonary sarcomatoid carcinoma. Am J Clin Oncol 39:215–222. https://doi.org/10.1097/COC.0000000000000101 CrossRefPubMed

Liu X, Pu Y, Cron K, Deng L, Kline J, Frazier WA, Xu H, Peng H, Fu YX, Xu MM (2015) CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med 21:1209–1215. https://doi.org/10.1038/nm.3931 CrossRefPubMedPubMedCentral

Liu B, Guo H, Xu J, Qin T, Guo Q, Gu N, Zhang D, Qian W, Dai J, Hou S, Wang H, Guo Y (2018a) Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses. MAbs 10:315–324. https://doi.org/10.1080/19420862.2017.1409319 CrossRefPubMed

Liu X, Liu L, Ren Z, Yang K, Xu H, Luan Y, Fu K, Guo J, Peng H, Zhu M, Fu YX (2018b) Dual targeting of innate and adaptive checkpoints on tumor cells limits immune evasion. Cell Rep 24:2101–2111. https://doi.org/10.1016/j.celrep.2018.07.062 CrossRefPubMed

Lococo F, Rapicetta C, Cardillo G, Stefani A, Margaritora S, Leuzzi G, Rossi G, Petracca Ciavarella L, Morandi U, Facciolo F, Ricchetti T, Cesario A, Paci M (2017a) Pathologic findings and long-term results after surgical treatment for pulmonary sarcomatoid tumors: a multicenter analysis. Ann Thorac Surg 103:1142–1150. https://doi.org/10.1016/j.athoracsur.2016.08.114 CrossRefPubMed

Lococo F, Torricelli F, Rossi G, Alifano M, Damotte D, Rapicetta C, Tamagnini I, Cavazza A, Piana S, Galeone C, Paci M, Ciarrocchi A (2017b) Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas. Lung Cancer 113:93–101. https://doi.org/10.1016/j.lungcan.2017.09.009 CrossRefPubMed

Maneenil K, Xue Z, Liu M, Boland J, Wu F, Stoddard SM, Molina J, Yang P (2018) Sarcomatoid carcinoma of the lung: the mayo clinic experience in 127 patients. Clin Lung Cancer 19:e323–e333. https://doi.org/10.1016/j.cllc.2017.12.008 CrossRefPubMed

Martin LW, Correa AM, Ordonez NG, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Rice DC (2007) Sarcomatoid carcinoma of the lung: a predictor of poor prognosis. Ann Thorac Surg 84:973–980CrossRefPubMed

Pecuchet N, Vieira T, Rabbe N, Antoine M, Blons H, Cadranel J, Laurent-Puig P, Wislez M (2017) Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities. Ann Oncol 28:1597–1604. https://doi.org/10.1093/annonc/mdx162 CrossRefPubMed

Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O’Rourke T, Narayanan S, Papadopoulos K, Fisher GA, Villalobos V, Prohaska SS, Howard M, Beeram M, Chao MP, Agoram B, Chen JY, Huang J, Axt M, Liu J, Volkmer JP, Majeti R, Weissman IL, Takimoto CH, Supan D, Wakelee HA, Aoki R, Pegram MD, Padda SK (2019) First-in-human, first-in-class Phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol 37:946–953. https://doi.org/10.1200/JCO.18.02018 CrossRefPubMedPubMedCentral

Sockolosky JT, Dougan M, Ingram JR, Ho CC, Kauke MJ, Almo SC, Ploegh HL, Garcia KC (2016) Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proc Natl Acad Sci USA 113:E2646–E2654. https://doi.org/10.1073/pnas.1604268113 CrossRefPubMedPubMedCentral

Suda K, Sato K, Shimizu S, Tomizawa K, Takemoto T, Iwasaki T, Sakaguchi M, Mitsudomi T (2014) Prognostic implication of predominant histologic subtypes of lymph node metastases in surgically resected lung adenocarcinoma. Biomed Res Int 2014:645681. https://doi.org/10.1155/2014/645681 CrossRefPubMedPubMedCentral

Theate I, van Baren N, Pilotte L, Moulin P, Larrieu P, Renauld JC, Herve C, Gutierrez-Roelens I, Marbaix E, Sempoux C, Van den Eynde BJ (2015) Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues. Cancer Immunol Res 3:161–172. https://doi.org/10.1158/2326-6066.CIR-14-0137 CrossRefPubMed

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Lerning PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454. https://doi.org/10.1056/NEJMoa1200690 CrossRefPubMedPubMedCentral

Velcheti V, Rimm DL, Schalper KA (2013) Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1). J Thorac Oncol 8:803–805. https://doi.org/10.1097/JTO.0b013e318292be18 CrossRefPubMedPubMedCentral

Vieira T, Girard N, Ung M, Monnet I, Cazes A, Bonnette P, Duruisseaux M, Mazieres J, Antoine M, Cadranel J, Wislez M (2013) Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma. J Thorac Oncol 8:1574–1577. https://doi.org/10.1097/01.JTO.0000437008.00554.90 CrossRefPubMed

Vieira T, Antoine M, Ruppert AM, Fallet V, Duruisseaux M, Giroux Leprieur E, Poulot V, Rabbe N, Sclick L, Beau-Faller M, Lacave R, Lavole A, Cadranel J, Wislez M (2014) Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lung. Lung Cancer 85:276–281. https://doi.org/10.1016/j.lungcan.2014.06.004 CrossRefPubMed

Vieira T, Antoine M, Hamard C, Fallet V, Duruisseaux M, Rabbe N, Rodenas A, Cadranel J, Wislez M (2016) Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. Lung Cancer 98:51–58. https://doi.org/10.1016/j.lungcan.2016.05.013 CrossRefPubMed

Weiskopf K (2017) Cancer immunotherapy targeting the CD47/SIRPα axis. Eur J Cancer 76:100–109. https://doi.org/10.1016/j.ejca.2017.02.013 CrossRefPubMed

Weiskopf K, Ring AM, Ho CC, Volkmer JP, Levin AM, Volkmer AK, Ozkan E, Fernhoff NB, van de Rijn M, Weissman IL, Garcia KC (2013) Engineered SIRPα variants as immunotherapeutic adjuvants to anti-cancer antibodies. Science 341:88–91. https://doi.org/10.1126/science.1238856 CrossRefPubMed

Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, Volkmer AK, Volkmer JP, Liu J, Lim JS, Yang D, Seitz G, Nguyen T, Wu D, Jude K, Guerston H, Barkal A, Trapani F, George J, Poirier JT, Gardner EE, Miles LA, de Stanchina E, Lofgren SM, Vogel H, Winslow MM, Dive C, Thomas RK, Rudin CM, van de Rijn M, Majeti R, Garcia KC, Weissman IL, Sage J (2016) CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J Clin Invest 126:2610–2620. https://doi.org/10.1172/JCI81603 CrossRefPubMedPubMedCentral

Xiao Z, Chung H, Banan B, Manning PT, Ott KC, Lin S, Capoccia BJ, Subramanian V, Hiebsch RR, Upadhya GA, Mohanakumar T, Frazier WA, Lin Y, Chapman WC (2015) Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma. Cancer Lett 360:302–309. https://doi.org/10.1016/j.canlet.2015.02.036 CrossRefPubMedPubMedCentral

Yendamuri S, Caty L, Pine M, Adem S, Bogner P, Miller A, Demmy TL, Groman A, Reid M (2012) Outcomes of sarcomatoid carcinoma of the lung: a surveillance, epidemiology, and end results database analysis. Surgery 152:397–402. https://doi.org/10.1016/j.surg.2012.05.007 CrossRefPubMed

Yoshida K, Tsujimoto H, Matsumura K, Kinoshita M, Takahata R, Matsumoto Y, Hiraki S, Ono S, Seki S, Yamamoto J, Hase K (2015) CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer. Cancer Med 4:1322–1333. https://doi.org/10.1002/cam4.478 CrossRefPubMedPubMedCentral

Yuki T, Sakuma T, Ohbayashi C, Yoshimura M, Tsubota N, Okita Y, Okada M (2007) Pleomorphic carcinoma of the lung: a surgical outcome. J Thorac Cardiovasc Surg 134:399–404CrossRefPubMed

Zehani A, Ayadi-Kaddour A, Marghli A, Maamouri H, Kassar L, Kilani T, El Mezni F (2014) Sarcomatoid carcinoma of the lung: retrospective study of 28 cases. Ann Pathol 34:124–129. https://doi.org/10.1016/j.annpat.2013.12.001 CrossRefPubMed

Zhai L, Spranger S, Binder DC, Gritsina G, Lauing KL, Giles FJ, Wainwright DA (2015) Molecular pathways: targeting IDO1 and other tryptophan dioxygenases for cancer immunotherapy. Clin Cancer Res 21:5427–5433. https://doi.org/10.1158/1078-0432.CCR-15-0420 CrossRefPubMedPubMedCentral

Zhao H, Wang J, Kong X, Li E, Liu Y, Du X, Kang Z, Tang Y, Kuang Y, Yang Z, Zhou Y, Wang Q (2016) CD47 promotes tumor invasion and metastasis in non-small cell lung cancer. Sci Rep 6:29719. https://doi.org/10.1038/srep29719 CrossRefPubMedPubMedCentral

Titel: PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy
verfasst von: Zhenlin Yang
Jiachen Xu
Renda Li
Yibo Gao
Jie He
Publikationsdatum: 14.09.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 12/2019
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-019-03023-w

Springer Medizin

PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2019

Are shape morphologies associated with survival? A potential shape-based biomarker predicting survival in lung cancer

Prognostic value and clinicopathological roles of phenotypes of tumour-associated macrophages in colorectal cancer

Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors

Brain metastasis as exclusion criteria in clinical trials involving extensive-stage small cell lung cancer

Co-targeting PI3K/Akt and MAPK/ERK pathways leads to an enhanced antitumor effect on human hypopharyngeal squamous cell carcinoma

Increased risk for cancer after stroke at a young age: etiological relevance or incidental finding?

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie